New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:02 EDTLJPCLa Jolla Pharmaceutical price target raised to $32 from $27 at Wedbush
Wedbush increased its price target on La Jolla after the company's GCS-100 drug facilitated statistically significant improvement in kidney function in CKD patients in a Phase 2a trial. The firm thinks the company will respond by taking the drug forward in CKD, and by activating clinical trials in multiple pipeline candidates. Wedbush keeps an Outperform rating on the stock.
News For LJPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
10:01 EDTLJPCOn The Fly: Analyst Initiation Summary
Today's noteworthy imitations include: ANSYS (ANSS) initiated with an Overweight at Mitsubishi UFJ... Antero Midstream (AM) initiated with a Buy at Janney Capital... Autodesk (ADSK) initiated with a Neutral at Mitsubishi UFJ... Cheesecake Factory (CAKE) initiated with a Buy at Maxim... Depomed (DEPO) initiated with a Buy at UBS... Fleetmatics (FLTX) initiated with a Market Perform at Avondale... Glaukos (GKOS) initiated with an Overweight at Piper Jaffray... La Jolla (LJPC) initiated with an Outperform at Cowen... Manhattan Associates (MANH) initiated with a Market Perform at Avondale... Metabolix (MBLX) initiated with a Buy at Rodman & Renshaw... Opower (OPWR) initiated with an Outperform at Avondale... Social Reality (SCRI) initiated with a Buy at Rodman & Renshaw... Splunk (SPLK) initiated with an Overweight at Mitsubishi UFJ... Sucampo (SCMP) initiated with a Buy at UBS... Ultragenyx (RARE) initiated with a Buy at H.C. Wainwright... Workday (WDAY) initiated with an Overweight at Mitsubishi UFJ.
06:15 EDTLJPCLa Jolla initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated La Jolla with an Outperform rating and $40 price target on shares. The analyst said La Jolla's lead candidate, LJPC-501, an angiotensin II vasoconstrictor and a key regulator of blood pressure, will succeed in its Phase III trial in late 2016 and estimates that peak U.S. sales potential of over $1B.
February 8, 2016
16:31 EDTLJPCVisium Asset Management 6.5% passive stake in La Jolla

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use